Arterial hypertension in obese patients: clinical and pathogenetic features

Posted on by adminLeave a comment

Prof. O.M. Korzh, prof. L.V. Cherkashyna, assoc. prof. L.M. Tsogoeva

Kharkiv National Medical University

Induced arterial hypertension (AH) is one of the forms of AH, the pathogenetic mechanisms of which are well studied: the main reason is the disruption of the functioning of visceral adipose tissue, which leads to activation of the renin-angiotensin-aldosterone system, imbalance of the sympathetic and parasympathetic systems, kidney damage, endothelial dysfunction of vessels and, in fact, to increased blood pressure (BP) and consolidation of AH. However, among this form of AH, additional mechanisms can be distinguished that play a special role in the formation of hypertension in obesity. This review describes such mechanisms as chronic inflammation, excessive salt intake, dysbiosis and environmental factors. Understanding these features of AH in obesity is of great importance for achieving target levels of AH. Special attention is paid to such forms of AH as masked and nocturnal hypertension, the timely diagnosis of which is critically important for effective treatment and improving prognosis.

Key words: arterial hypertension, clinical phenotype, obesity, pathogenetic mechanisms.

https://doi.org/10.15407/internalmed2025.01.096

Download.PDF (ukr)

Cite:

Корж О.М., Черкашина Л.В., Цогоєва Л.М. Артеріальна гіпертензія у пацієнтів із ожирінням: клініко-патогенетичні особливості/Східноєвропейський журнал внутрішньої та сімейної медицини. – 2025. – № 1. – С. 96-101. doi.org/10.15407/internalmed2025.01.096

Korzh OM, Cherkashyna LV, Tsogoeva LM. Arterial hypertension in obese patients: clinical and pathogenetic features. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini. 2025(1):96-101. doi.org/10.15407/internalmed2025.01.096

References:

  1. Natsis M, Antza C, Doundoulakis I, Stabouli S, Kotsis V. Hypertension in Obesity: Novel Insights. Curr Hypertens Rev. 2020;16(1):30-36. https://doi.org/10.2174/1573402115666190415154603
  2. Hamjane N, Benyahya F, Nourouti NG, Mechita MB, Barakat A. Cardiovascular diseases and metabolic abnormalities associated with obesity: What is the role of inflammatory responses? A systematic review. Microvasc Res. 2020;131:104023. https://doi.org/10.1016/j.mvr.2020.104023
  3. Dlamini Z, Hull R, Makhafola TJ, Mbele M. Regulation of alternative splicing in obesity-induced hypertension. Diabetes Metab Syndr Obes. 2019;12:1597-1615. https://doi.org/10.2147/DMSO.S188680
  4. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107. https://doi.org/10.1016/j.metabol.2018.10.011
  5. Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the study of obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30(6):1047-55. https://doi.org/10.1097/HJH.0b013e3283537347
  6. Carey R, Calhoun D, Bakris G, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):53-90. https://doi.org/10.1161/HYP.0000000000000084
  7. Schiffrin E. Immune mechanisms in hypertension and vascular injury. Clin Sci (Lond). 2014;126(4):267-74. doi:10.1042/CS20130407.
  8. Kalathookunnel A, Lian Z, Wu H. T Cells in Adipose Tissue in Aging. Front Immunol. 2018;9:2945. https://doi.org/10.3389/fimmu.2018.02945
  9. Xiao L, Harrison D. Inflammation in Hypertension. Can J Cardiol. 2020;36(5):635-47. https://doi.org/10.1016/j.cjca.2020.01.013
  10. Ge W, Guo X, Song X, et al. The role of immunoglobulin E and mast cells in hypertension. Cardiovasc Res. 2022;118(14):2985-99. https://doi.org/10.1093/cvr/cvac010
  11. Mutchler S, Kirabo A, Kleyman T. Epithelial Sodium Channel and Salt-Sensitive Hypertension. Hypertension. 2021;77(3):759-67. https://doi.org/10.1161/HYPERTENSIONAHA.120.14481
  12. Kirabo A. A new paradigm of sodium regulation in inflammation and hypertension. Am J Physiol Regul Integr Comp Physiol. 2017;313(6):706-10. https://doi.org/10.1152/ajpregu.00250.2017
  13. Wenzel U, Bode M, Kurts C, Ehmke H. Salt, inflammation, IL-17 and hypertension. Br J Pharmacol. 2019;176(12):1853-63. https://doi.org/10.1111/bph.14359
  14. He F, Tan M, Ma Y, MacGregor G. Salt Reduction to Prevent Hypertension and Cardiovascular Disease. J Am Coll Cardiol. 2020;75(6):632-47. https://doi.org/10.1016/j.jacc.2019.11.055
  15. He F, Campbell N, Woodward M, MacGregor G. Salt reduction to prevent hypertension: the reasons of the controversy. European Heart Journal. 2021;42(25):2501-5. https://doi.org/10.1093/eurheartj/ehab274
  16. Messerli F, Hofstetter L, Syrogiannouli L, et al. Sodium intake, life expectancy, and allcause mortality. European Heart Journal. 2021;42(21):2103-12. https://doi.org/10.1093/eurheartj/ehaa947
  17. Mente A, O’Donnell M, Yusuf S. Sodium and health: another challenge to the current dogma. European Heart Journal. 2021;42(21):2116-8. https://doi.org/10.1093/eurheartj/ehaa1093
  18. O’Donnell M, Mente A, Alderman M, et al. Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. European Heart Journal. 2020;41(35):3363-73. https://doi.org/10.1093/eurheartj/ehaa586
  19. Grylls A, Seidler K, Neil J. Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics. Biomedicine & Pharmacotherapy. 2021;137:111334. https://doi.org/10.1016/j.biopha.2021.111334
  20. Robles-Vera I, Toral M, Duarte J. Microbiota and Hypertension: Role of the Sympathetic Nervous System and the Immune System. Am J Hypertens. 2020;33(10):890-901. https://doi.org/10.1093/ajh/hpaa103
  21. Asadi A, Mehr N, Mohamadi M, et al. Obesity and gut-microbiota-brain axis: A narrative review. J Clin Lab Anal. 2022;36(5):24420. https://doi.org/10.1002/jcla.24420
  22. Hall J, do Carmo J, da Silva A, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006. https://doi.org/10.1161/CIRCRESAHA.116.305697
  23. Kupcikova Z, Fecht D, Ramakrishnan R, et al. Road traffic noise and cardiovascular disease risk factors in UK Biobank. European Heart Journal. 2021;42(21):2072-84. https://doi.org/10.1093/eurheartj/ehab121
  24. Munzel T, Steven S, Hahad O, Daiber A. Noise and cardiovascular risk: nighttime aircraft noise acutely triggers cardiovascular death. European Heart Journal. 2021;42(8):844-6. https://doi.org/10.1093/eurheartj/ehaa984
  25. Mannucci P, Ancona C. Noise and air pollution as triggers of hypertension. European Heart Journal. 2021;42(21):2085-7. https://doi.org/10.1093/eurheartj/ehab104
  26. Fujiwara T, Yano Y, Hoshide S, et al. Association of Cardiovascular Outcomes With Masked Hypertension Defined by Home Blood Pressure Monitoring in a Japanese General Practice Population. JAMA Cardiol. 2018;3(7):583-90. https://doi.org/10.1001/jamacardio.2018.1233
  27. Penmatsa K, Biyani M, Gupta A. Masked Hypertension: Lessons for the Future. Ulster Med J. 2020;89(2):77-82.
  28. Tientcheu D, Ayers C, Das S, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension. J Am Coll Cardiol. 2015;66(20):2159-69. https://doi.org/10.1016/j.jacc.2015.09.007
  29. Coccina F, Pierdomenico A, De Rosa M, et al. Risk of Atrial Fibrillation in Masked and White Coat Uncontrolled Hypertension. Am J Hypertens. 2021;34(5):504-10. https://doi.org/10.1093/ajh/hpaa185
  30. Yang W, Melgarejo J, Thijs L, et al. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA. 2019;322(5):409-20. https://doi.org/10.1001/jama.2019.9811
  31. Xia J, Zhang D, Kang Y, et al. The prevalence of masked hypertension and masked uncontrolled hypertension in relation to overweight and obesity in a nationwide registry in China. Hypertens Res. 2022;45:1690-700. https://doi.org/10.1038/s41440-022-01005-z
  32. Tadic M, Cuspidi C, Grassi G, Manci G. Isolated Nocturnal Hypertension: What Do We Know and What Can We Do? Integr Blood Press Control. 2020;13:63-9. https://doi.org/10.2147/IBPC.S223336
  33. Kario K. Nocturnal hypertension: new technology and evidence. Hypertension. 2018;71(6):997-1009. https://doi.org/10.1161/HYPERTENSIONAHA.118.10971
  34. Parodi R, Brandani L, Romero C, Klein M. Resistant hypertension: Diagnosis, evaluation, and treatment practical approach. Eur J Intern Med. 2024;123:23-28. https://doi.org/10.1016/j.ejim.2023.12.026